Lophius Biosciences, a developer of T-cell-based diagnostic test systems in Regensburg, Germany, has announced the successful completion of a new round of financing. VRD GmbH and WIC GmbH have joined existing investors and allowed the company to raise approximately €4 million.
The financial commitment validates the successful development of the CE-marked T-Track CMV and EBV tests and T-Track TB, which are based on the company's two patented technology platforms, said Dr. Michael Lutz, Managing Director of Lophius Biosciences, in a press release.
The company has also announced the appointment of Prof. Dr. Ralf Wagner to the position of Managing Director. Former CEO of GeneArt AG and a professor of molecular biology and gene therapy at the University of Regensburg, Wagner will join forces with Lutz to further drive the company's evolution as a fully integrated player in the field of T-cell based diagnostics.